Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM155 in Refractory DLBCL
NCT00498914Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Jun 2007
- Primary completion
- Apr 2009
- Modality
- Classical Binding Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of sepantronium in diffuse large B-cell lymphoma (DLBCL), sponsored by Astellas Pharma. Started Jun 2007; status: terminated.
02
Drugs
sepantronium
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00498914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498914.